Form 4: Alnylam Pharmaceuticals Director Acquires Shares and Stock Options

Director Olivier Brandicourt reports acquisition of common stock and stock options in Alnylam Pharmaceuticals.

Summary

• On May 8, 2025, Olivier Brandicourt, a director of Alnylam Pharmaceuticals, acquired 775 shares of common stock represented by restricted stock units (RSUs).
• Brandicourt also acquired stock options for 1,558 shares of common stock with an exercise price of $258.35.
• The RSUs and stock options vest in full upon the earlier of the first anniversary of the grant date (May 8, 2026) or the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
• Following these transactions, Brandicourt directly owns 775 shares of common stock and stock options for 1,558 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of shares and stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like Alnylam Pharmaceuticals. These filings provide transparency into the trading activities of company insiders.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Alnylam Pharmaceuticals, Olivier Brandicourt, Director, Stock Options, RSUs, Form 4, Acquisition, Common Stock